We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$821M
AUM Growth
-$848M
Cap. Flow
-$726M
Cap. Flow %
-88.46%
Top 10 Hldgs %
68.05%
Holding
41
New
9
Increased
2
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$44.5M
2
HRTX icon
Heron Therapeutics
HRTX
+$31.3M
3
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$26.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$25.7M
5
MTEM
Molecular Templates, Inc.
MTEM
+$20.6M

Top Sells

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$123M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$98.2M
3
AKBA icon
Akebia Therapeutics
AKBA
+$95.5M
4
CDNA icon
CareDx
CDNA
+$79.1M
5
CYTK icon
Cytokinetics
CYTK
+$78.9M

Sector Composition

Rank Sector Weight
1 Healthcare 84.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
1
MacroGenics
MGNX
$240M
$94.4M 11.5%
3,747,298
-294,237
-7% -$8.03M
GNMK
2
DELISTED
GenMark Diagnostics, Inc
GNMK
$75.3M 9.17%
5,299,863
-1,594,618
-23% -$24.4M
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$64.6M 7.87%
138,727
-97,126
-41% -$49.1M
ATRA icon
4
Atara Biotherapeutics
ATRA
$73.6M
$60.7M 7.4%
187,421
-22,108
-11% -$7.53M
KDMN
5
DELISTED
Kadmon Holdings, Inc.
KDMN
$54.9M 6.69%
14,007,548
-1,703,000
-11% -$7.15M
APTO
6
DELISTED
Aptose Biosciences, Inc.
APTO
$48M 5.84%
17,766
+2,277
+15% +$5.68M
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.92B
$46.3M 5.64%
+2,369,709
New +$44.5M
CGEN icon
8
Compugen
CGEN
$220M
$42.9M 5.22%
2,637,421
-1,440,000
-35% -$23.6M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$6.1B
$36.4M 4.43%
2,374,392
-468,992
-16% -$8.8M
APRE icon
10
Aprea Therapeutics
APRE
$7.86M
$35.1M 4.28%
72,971
+10,362
+17% +$5.8M
LMNL
11
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$34.3M 4.18%
308,463
-20,268
-6% -$2.74M
ASMB icon
12
Assembly Biosciences
ASMB
$516M
$32.4M 3.95%
164,156
-100,472
-38% -$25.3M
TCRR
13
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$30.7M 3.74%
+1,509,819
New +$26.5M
HRTX icon
14
Heron Therapeutics
HRTX
$94.1M
$29.7M 3.62%
+2,005,218
New +$31.3M
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
$28.7M 3.5%
+602,732
New +$25.7M
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.7M 2.64%
3,844,994
-805,571
-17% -$3.84M
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
$19M 2.31%
+115,734
New +$20.6M
SIOX
18
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$15M 1.82%
3,236,335
-416,968
-11% -$1.38M
STXS icon
19
Stereotaxis
STXS
$133M
$11.2M 1.37%
3,135,176
-523,361
-14% -$2.02M
CASI
20
DELISTED
CASI Pharmaceuticals
CASI
$10M 1.22%
+656,000
New +$12.4M
ATNM icon
21
Actinium Pharmaceuticals
ATNM
$26.3M
$7.69M 0.94%
793,170
-440,163
-36% -$4.85M
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$7.63M 0.93%
202,667
– –
OMER icon
23
Omeros
OMER
$863M
$4.89M 0.6%
484,042
-3,685,830
-88% -$47.5M
ADMA icon
24
ADMA Biologics
ADMA
$2.01B
$3.72M 0.45%
1,558,290
-1,100,000
-41% -$3.02M
DFHTU
25
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$2.66M 0.32%
+250,000
New +$2.63M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Consonance Capital Management held 41 positions worth $821M, down 51% from $1.67B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Consonance Capital Management withdrew a net $726M in Q3 2020, closing 14 positions and reducing 15 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $123M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Protagonist Therapeutics worth $46.3M.

  • Consonance Capital Management's largest Q3 2020 buy was Protagonist Therapeutics: 2,369,709 shares worth $46.3M.
  • Consonance Capital Management added most to Aprea Therapeutics in Q3 2020, an estimated $5.8M increase.
  • Consonance Capital Management's biggest Q3 2020 reduction was Mersana Therapeutics, cutting an estimated $49.1M.
  • Consonance Capital Management fully exited Karyopharm Therapeutics in Q3 2020, selling an estimated $123M.
  • Consonance Capital Management's ten largest holdings make up 68% of its $821M portfolio in Q3 2020.
  • Consonance Capital Management opened 9 new positions and closed 14 in Q3 2020.
  • Consonance Capital Management's portfolio value fell 51% quarter-over-quarter to $821M.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.